EX-99.1 2 afib-20240401exhibit991.htm EX-99.1 Document
Press ReleaseExhibit 99.1
image_1.jpg
Acutus Medical Reports Fourth Quarter and Full Year 2023 Financial Results
CARLSBAD, Calif., April 1, 2024 (GLOBE NEWSWIRE) — Acutus Medical, Inc. (“Acutus” or the “Company”) (Nasdaq: AFIB) today reported results for the fourth quarter and full year ended December 31,2023.
Recent Highlights:
•Announced strategic realignment of resources and corporate restructuring on November 8, 2023 with the objective of optimizing financial position and maximizing free cash flow.

•The Continuing Operations focuses on the implementation of the business model to shift to solely support the manufacturing and distribution of Medtronic’s left-heart access product portfolio.

•Discontinued Operations relates to the Company’s mapping and ablation business that was wound down as part of the strategic realignment of resources and corporate restructuring.

•Fourth quarter revenue from Continuing Operations of $2.4 million grew 118% year-over-year, from $1.1 million in the year ago fourth quarter.

•Full year revenue from Continuing Operations of $7.2 million, grew 136% year-over-year from $3.0 million in 2022.     
Full Year 2024 Financial Results
Revenue from Continuing Operations was $2.4 million for the fourth quarter of 2023, an increase of 118% compared to $1.1 million for the fourth quarter of 2022. The improvement over last year was primarily driven by sales through the Company’s distribution agreement with Medtronic.

Full Year 2024 Financial Results
Revenue from Continuing Operations was $7.2 million for the full year of 2023, an increase of 136% compared to $3.0 million for the full year of 2022. The improvement over last year was driven by sales through the Company’s distribution agreement with Medtronic.
Gross margin on a GAAP basis was negative 44% for the full year ended December 31,2023 compared to negative 63% for the full year ended December 31, 2022. The improvement was driven by higher production volumes related to left-heart access manufacturing, operational efficiencies implemented on the production line, and reduced manufacturing overhead expenses.
Operating expenses for continuing operations, consisting of research and development, and selling, general and administrative expenses on a GAAP basis were $17.5 million for the year ended December 31,2023 compared to $23.4 million for the same period last year. The decrease in operating expenses resulted from reduced discretionary spend, and the reprioritization of certain research and development programs.
Net loss on continuing operations on a GAAP basis was $11.9 million for the full year ended December 31, 2023 and net loss per share was $0.41 on a weighted average basic and diluted outstanding share count of 29.1 million, compared to a net income of $28.8 million and a net earnings per share of $1.02 on a weighted average basic outstanding share count of 28.5, and a net earnings per share of $0.78 on a weighted average diluted outstanding share count of 37.2 million for the same quarter last year. The decrease in net Income is primarily related to the change in the gain on sale of the Left Heart Access business to Medtronic from the year ended December 31, 2022.

#97472457v2    
image_1.jpg
Cash, cash equivalents, marketable securities and restricted cash were $29.4 million as of December 31, 2023.

Loss on Discontinued Operations
Loss on discontinued operations was $69.7 million for the year ended December 31, 2023, compared to $68.4 million for the year ended December 31, 2022. This increase of $1.3 million was primarily attributable to an increase in restructuring expense of $21.9 million, which includes the $16.4 million loss recorded on classification of held for sale, offset by a decrease in selling and marketing expenses of $8.5 million, a decrease in research and development expenses of $6.7 million and an improvement in gross profit margin of 2,900 basis points, during the year ended December 31, 2023.

Outlook
Due to the announced plan to realign resources to support the left-heart access distribution business and exit from the electrophysiology mapping and ablation businesses, the Company will no longer provide financial guidance.
About Acutus
Acutus is focused on the production of left-heart access products under its distribution agreement with Medtronic, Inc. Founded in 2011, Acutus is based in Carlsbad, California.
Caution Regarding Forward-Looking Statements
This press release includes statements that may constitute “forward-looking” statements, usually containing the words “believe,” “estimate,” “project,” “expect” or similar expressions. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, the Company’s ability to continue to manage expenses and cash burn rate at sustainable levels, successful completion of the Company’s restructuring plan, continued acceptance of the Company’s left-heart access products in the marketplace, the effect of global economic conditions on the ability and willingness of Medtronic to purchase the Company’s left-heart access products and the timing of such purchases, competitive factors, changes resulting from healthcare policy in the United States and globally including changes in government reimbursement of procedures, dependence upon third-party vendors and distributors, timing of regulatory approvals, the Company’s ability to maintain its listing on Nasdaq, and other risks discussed in the Company’s periodic and other filings with the Securities and Exchange Commission. By making these forward-looking statements, Acutus undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.

Investor Contact:
Chad Hollister
Acutus Medical, Inc.
investors@acutus.com


#97472457v2    
image_1.jpg
Acutus Medical, Inc.
Consolidated Balance Sheets
(in thousands, except share and per share amounts)December 31,
2023		December 31,
2022
ASSETS
Current assets:
Cash and cash equivalents$19,170 $25,584 
Marketable securities, short-term3,233 44,863 
Restricted cash, short-term7,030 5,764 
Accounts receivable11,353 17,919 
Inventory4,278 1,794 
Employer retention credit receivable— 4,703 
Prepaid expenses and other current assets678 1,254 
Current assets of discontinued operations (Note 3)510 15,986 
Total current assets46,252 117,867 
Property and equipment, net825 1,669 
Right-of-use assets, net3,189 3,872 
Other assets94 94 
Non-current assets of discontinued operations (Note 3)3,600 9,938 
Total assets$53,960 $133,440 
LIABILITIES AND STOCKHOLDERS' (DEFICIT) EQUITY
Current liabilities:
Accounts payable2,761 2,473 
Accrued liabilities2,887 3,310 
Contingent consideration, short-term— 1,800 
Operating lease liabilities, short-term718 319 
Long-term debt, current portion1,864 — 
Warrant liability409 3,346 
Current liabilities of discontinued operations (Note 3)10,303 8,624 
Total current liabilities18,942 19,872 
Operating lease liabilities, long-term3,243 4,103 
Long-term debt32,654 34,434 
Other long-term liabilities— 12 
Total liabilities54,839 58,421 
Commitments and contingencies (Note 12)
Stockholders' (deficit) equity
Preferred stock, $0.001 par value; 5,000,000 shares authorized as of December 31, 2023 and December 31, 2022; 6,666 shares of the preferred stock, designated as Series A Common Equivalent Preferred Stock, are issued and outstanding as of December 31, 2023 and December 31, 2022, respectively
— — 
Common stock, $0.001 par value; 260,000,000 shares authorized as of December 31, 2023 and December 31, 2022; 29,313,667 and 28,554,656 shares issued and outstanding as of December 31, 2023 and December 31, 2022, respectively
29 29 
Additional paid-in capital599,935 594,173 
Accumulated deficit(599,977)(518,314)
Accumulated other comprehensive loss(866)(869)
Total stockholders' equity(879)75,019 
Total liabilities and stockholders' equity$53,960 $133,440 


#97472457v2    
image_1.jpg
Acutus Medical, Inc.
Consolidated Statements of Operations and Comprehensive Loss
Year Ended December 31, 2023
(in thousands, except share and per share amounts)20232022
Revenue$7,164 $3,031 
Cost of products sold10,301 4,941 
Gross loss
(3,137)(1,910)
Operating expenses (income):
Research and development3,482 3,118 
Selling, general and administrative14,066 20,315 
Goodwill impairment— 12,026 
Change in fair value of contingent consideration123 1,053 
Gain on sale of business(9,080)(79,465)
Total operating expenses (income)
8,591 (42,953)
(Loss) income from operations
(11,728)41,043 
Other income (expense):
Loss on debt extinguishment— (7,947)
Change in fair value of warrant liability2,937 33 
Interest income2,588 868 
Interest expense(5,655)(5,149)
Total other expense, net(130)(12,195)
(Loss) income from continuing operations before income taxes
(11,858)28,848 
Income tax expense63 15 
Net (loss) income from continuing operations
(11,921)28,833 
Discontinued operations:
Loss from discontinued operations before income taxes(69,530)(68,382)
Income tax expense - discontinued operations
212 67 
Loss from discontinued operations(69,742)(68,449)
Net loss$(81,663)$(39,616)
Other comprehensive income (loss):
Unrealized gain on marketable securities7 39 
Foreign currency translation adjustment(4)(691)
Comprehensive loss$(81,660)$(40,268)
Net (loss) earnings per share, basic:
     (Loss) income from continuing operations
$(0.41)$1.02 
     Loss from discontinued operations $(2.40)$(2.42)
     Net loss per common share, basic$(2.81)$(1.40)
Net earnings (loss) per share, diluted:
     (Loss) income from continuing operations
$(0.41)$0.78 
     Loss from discontinued operations$(2.40)$(2.42)

#97472457v2    
image_1.jpg
     Net loss per common share, diluted $(2.81)$(1.40)
Weighted average number of common shares outstanding, basic 29,095,294 28,471,389 
Weighted average number of common shares outstanding, diluted- continuing operations29,095,294 37,152,367 
Weighted average number of common shares outstanding, diluted- discontinued operations and net loss per common share29,095,294 28,471,389 


#97472457v2    
image_1.jpg
Acutus Medical, Inc.
Consolidated Statements of Cash Flows
Year Ended December 31, 2023
(in thousands)20232022
Cash flows from operating activities
Net loss$(81,663)$(39,616)
Less: Loss on discontinued operations69,742 68,449 
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation expense191 339 
AcQMap Systems converted to sales— — 
Sales-type lease gain— — 
Amortization of intangible assets— 220 
Non-cash stock-based compensation expense3,032 3,400 
Accretion of discounts on marketable securities, net
(1,428)(24)
Amortization of debt issuance costs571 850 
Amortization of operating lease right-of-use assets683 649 
Loss on debt extinguishment— 7,947 
Goodwill impairment— 12,026 
Gain on sale of business, net(9,080)(79,465)
Direct costs paid related to sale of business— (4,027)
Change in fair value of warrant liability(2,937)(33)
Loss on disposal of property and equipment— — 
Change in fair value of contingent consideration123 1,053 
Changes in operating assets and liabilities:
Accounts receivable(1,074)(464)
Inventory(2,484)(65)
Employer retention credit receivable4,703 (4,703)
Prepaid expenses and other current assets656 2,452 
Other assets— — 
Accounts payable288 (204)
Accrued liabilities(700)1,434 
Operating lease liabilities(461)(526)
Other long-term liabilities(12)(538)
Net cash used in operating activities - continuing operations(19,850)(30,846)
Net cash used in operating activities - discontinued operations(43,268)(58,071)
Net cash used in operating activities(63,118)(88,917)
Cash flows from investing activities
Proceeds from sale of business17,000 70,000 
Purchases of available-for-sale marketable securities(39,765)(54,508)
Sales of available-for-sale marketable securities750 18,599 
Maturities of available-for-sale marketable securities82,000 74,642 
Purchases of property and equipment(219)(228)
Net cash provided by investing activities - continuing operations59,766 108,505 
Net cash used in investing activities - discontinued operations(1,211)(3,754)
Net cash provided by investing activities58,555 104,751 
Cash flows from financing activities
Repayment of debt— (44,550)
Penalty fees paid for early prepayment of debt— (1,063)
Borrowing under new debt, net of fees— 34,825 
Payment of debt issuance costs(490)(626)
Proceeds from the exercise of stock options4 67 
Repurchase of common shares to pay employee withholding taxes— (111)
Proceeds from employee stock purchase plan25 214 
Payment of contingent consideration(1,923)(372)
Net cash used in financing activities - continuing operations(2,384)(11,616)
Net cash used in financing activities - discontinued operations(280)— 
Net cash used in financing activities(2,664)(11,616)

#97472457v2    
image_1.jpg
Effect of exchange rate changes on cash, cash equivalents and restricted cash2,079 2,909 
Net change in cash, cash equivalents and restricted cash(5,148)7,127 
Cash, cash equivalents and restricted cash, at the beginning of the period31,348 24,221 
Cash, cash equivalents and restricted cash, at the end of the period$26,200 $31,348 
Supplemental disclosure of cash flow information:
Cash paid for interest$5,012 $4,231 
Supplemental disclosure of noncash investing and financing activities:
Changes between assets and liabilities in discontinued operations$5,445 $(11,341)
Accounts receivable from sale of business$9,360 $17,000 
Change in unrealized (gain) loss on marketable securities$(7)$(39)
Change in unpaid purchases of property and equipment$— $54 
Contingent consideration escrow release$— $381 
Net book value on AcQMap system sales-type leases$— $244 
Amount of debt proceeds allocated to warrant liability$— $3,379 


#97472457v2